부산대학교 도서관

An HIV vaccine administered at birth with successive boosting during infancy will induce anti-HIV neutralizing and non-neutralizing antibody responses and HIV-specific cellular immunity that will reduce the risk of HIV infection via breastfeeding. Interestingly, while only a short-lived ADCC response was detectable in infant HIV vaccinees from the PACTG 230 trial [[24]] (Table 1), durable HIV-specific ADCC responses were obtained in infant RMs immunized with an HIV vaccine [[54]], suggesting that further studies involving non-neutralizing antibody responses in the context of pediatric HIV vaccination are necessary. The fact that the most recent adult HIV vaccine trial (HVTN 702), done in South Africa, which tested a canarypox vector-based vaccine (ALVAC-HIV) with HIV subtype C gp120 protein adjuvanted with MF-59, was recently discontinued due to lack of efficacy [[67]] highlights the need to evaluate promising next-generation immunogens. [Extracted from the article]